The value of glucocorticoid combined with terbutaline in the treatment of acute exacerbation of COPD
糖皮质激素联合特布他林治疗慢阻肺急性加重期的价值

摘要

目的 研究糖皮质激素联合特布他林治疗慢阻肺急性加重期的效果与价值。方法 选择2021年02月－2022年02月到本院治疗慢阻肺急性加重期患者104例，按照不同的治疗方式，分为实验组与对照组，分析两组治疗效果。结果 实验组治疗效果50（96.15％）优于对照组治疗效果44（84.62％），P＜0.05；治疗前，两组患者血气各项指标（PaO2、PaCO2、PH值、呼吸困难评分）对比，P＞0.05；治疗后，两组患者血气各项指标（PaO2、PaCO2、PH值、呼吸困难评分）对比，实验组各项指标更优，P＜0.05；实验组心肺功能指标优于对照组，P＜0.05；实验组患者不良反应发生率2（3.85%）低于对照组9（17.31%），P＜0.05。结论 运用糖皮质激素联合特布他林药物对慢阻肺急性加重期患者治疗，疗效显著，安全性高，可运用。

Abstract

Objective To study the effect and value of glucocorticoid combined with terbutaline in the treatment of acute exacerbation of COPD.
Methods from February 2021 to February 2022, 104 patients with acute exacerbation of COPD were selected and divided into experimental group and control group according to different treatment methods. The treatment effects of the two groups were analyzed.
Results the treatment effect of the experimental group was 50 (96.15%) better than that of the control group 44 (84.62%), P < 0.05; Before treatment, the blood gas indexes (PaO2, PaCO2, pH value, dyspnea score) of the two groups were compared, P > 0.05; After treatment, the indexes of blood gas (PaO2, PaCO2, pH value, dyspnea score) of the two groups were compared, and the indexes of the experimental group were better, P < 0.05; The indexes of cardiopulmonary function in the experimental group were better than those in the control group (P < 0.05); The incidence of adverse reactions in the experimental group 2 (3.85%) was lower than that in the control group 9 (17.31%), P < 0.05.
Conclusion   glucocorticoid combined with terbutaline is effective and safe in the treatment of patients with acute exacerbation of COPD.